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Abstract
The concept of the high‐affinity state postulates that a
certain subset of G‐protein‐coupled receptors is primarily
responsible for receptor signaling in the living brain.
Assessing the abundance of this subset is thus potentially
highly relevant for studies concerning the responses of
neurotransmission to pharmacological or physiological sti-
muli and the dysregulation of neurotransmission in neuro-
logical or psychiatric disorders. The high‐affinity state is
preferentially recognized by agonists in vitro. For this
reason, agonist tracers have been developed as tools for
the noninvasive imaging of the high‐affinity state with
positron emission tomography (PET). This review provides
an overview of agonist tracers that have been developed for
PET imaging of the brain, and the experimental paradigms
that have been developed for the estimation of the relative
abundance of receptors configured in the high‐affinity state.
Agonist tracers appear to be more sensitive to endogenous
neurotransmitter challenge than antagonists, as was origin-
ally expected. However, other expectations regarding
agonist tracers have not been fulfilled. Potential reasons
for difficulties in detecting the high‐affinity state in vivo are
discussed.
© 2018 The Authors. Medicinal Research Reviews Published by Wiley Periodicals, Inc.
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1 | INTRODUCTION
Noninvasive imaging of neurotransmitter receptors with positron emission tomography (PET) provides insights into
the number of receptors expressed in the brain and the functioning of brain networks. Analysis of the imaging data
yields information about the role of particular neurotransmitters in the functioning of the brain in health as well as
in neuropsychiatric disorders, including syndromes characterized by cognitive dysfunction.
Neurotransmitters bind to receptors that are either ligand‐gated ion channels (LGICs) or G‐protein‐coupled
receptors (GPCRs). For some neurotransmitters, all receptors belong to a single receptor superfamily, for example,
all known dopamine receptors are GPCRs. Other neurotransmitters bind to receptors from both superfamilies, for
example, there are LGIC‐ and GPCR‐type receptors of the neurotransmitters acetylcholine and glutamate.
The signaling mechanism of LGICs is comparatively simple and quick—neurotransmitter binding opens the ionic
channel that the receptor itself forms. A quick (millisecond time scale) and usually short‐lasting postsynaptic response
is thus obtained. GPCRs, on the other hand, affect their downstream signaling pathways through the mediation of
trimeric proteins called G‐proteins (Figure 1). The GPCR signaling mechanism is slower (second time scale) and more
energy‐consuming than that of LGICs, but long lasting and much more versatile. Due to this versatility, GPCRs are the
most popular targets for drugs in clinical use.1,2 GPCR‐target drugs or ligands, can be described as agonists or
antagonists depending on their effect on the receptor. Agonist drugs can be broadly defined as substances that act
like the endogenous neurotransmitter (by binding to the receptor and inducing a physiological response), whereas
antagonist drugs bind but do not induce a response and can block the action of the endogenous neurotransmitter.
In vitro studies in membrane homogenates from cultured cells or isolated tissues have shown that in a single
population of GPCRs to which antagonist drugs have a single affinity, agonist drugs recognize two distinct receptor
subpopulations: one for which they have high affinity and one for which they have low affinity. The existence of a receptor
subpopulation that possesses high‐affinity toward the agonists (dubbed “high‐affinity state,” Rhigh) has been demonstrated
for numerous neurotransmitter GPCRs including dopaminergic,3,4 serotonergic,5–7 muscarinic,8 and opioid receptors.9 The
F IGURE 1 Simplified signaling mechanisms of ligand‐gated ion channels (A) and G‐protein‐coupled receptors
(B). If an agonist (represented by a triangle) binds to a channel, the channel opens and ions (represented by small
diamonds) can enter the cell. If the agonist binds to a receptor, the G‐protein (represented by an ellipse) dissociates
from the receptor complex and activates specific effector proteins
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high‐affinity state is commonly thought to be composed of receptor molecules bound to G‐proteins. A crystal structure of
such an activated state of the receptor, in complex with the G‐protein, was first obtained in 2011.10
The relationship between G‐protein coupling and high‐affinity toward the agonist gave rise to a hypothesis that
the relative abundance of Rhigh may characterize the responsiveness of the synaptic signaling machinery to agonist
levels. Indeed, alterations of the fraction of receptors configured in the high‐affinity state, as measured in
membrane homogenates, were found in pathological states associated with dysregulation of neurotransmission. For
instance, the relative abundance of the high‐affinity state of µ‐opioid receptors was decreased in guinea pigs after
chronic morphine treatment,11 while the high‐affinity state of muscarinic M1 receptors was downregulated in
Alzheimer’s disease.12,13 Upregulation of the high‐affinity state of dopamine D2 receptors has been reported in
several animal models of psychosis.14,15
Assessing the availability of Rhigh may, therefore, provide more valuable information about the state of
neurotransmission in vivo than assessing the availability of total receptors. Given that agonists preferentially bind
to Rhigh, this hypothesis spurred the development of agonist PET tracers and their use for neuroreceptor imaging.
In this study we will review and discuss the molecular basis of the high‐affinity state, inherent advantages and
shortcomings of agonist PET tracers stemming from their preferential binding to the high‐affinity state, agonist PET
tracers currently available for receptor imaging, experimental methods used for the imaging of high‐affinity state in
vivo, and evidence collected with these methods.
2 | NATURE OF THE HIGH‐AFFINITY STATE OF GPCRS
2.1 | G‐protein‐dependent high‐affinity state
The canonical view of the nature of the high‐affinity state is based on the so‐called ternary complex model of G‐protein
signaling which originates from the studies of agonist binding to β‐adrenergic receptors in membrane homogenates.16,17
This model claims that a “ternary” complex must form to launch the G‐protein signaling cascade, consisting of agonist,
receptor, and G‐protein. Positive cooperativity between receptor‐agonist and receptor‐G‐protein binding creates the
separation of the total receptor population into high‐ and low‐affinity states. For the agonist, receptors complexed with G‐
proteins form the high‐affinity state, whereas free receptor molecules represent the low‐affinity state. Indeed, the
preference of ligands for the G‐protein‐bound high‐affinity state was found to correlate with their intrinsic activity.18–20
Several newer and more sophisticated versions of the ternary complex model have been developed to account for
pharmacological phenomena such as constitutive activity (presence of baseline signaling in the absence of agonists) and
inverse agonism (existence of ligands that decrease rather than increase the level of signaling relative to baseline). These
models imply the existence of more than two receptor species with different affinities for the agonist but the main premise
remains the same: G‐protein binding is the main factor that determines the receptor’s affinity toward the agonist.21,22
An important feature of the G‐protein‐dependent high‐affinity state is its sensitivity to guanosine triphosphate
(GTP). Indeed, the high‐affinity state of GPCRs detected in membrane homogenates usually disappears upon GTP
addition.3–9 The reason for this is that the canonical G‐protein signaling cascade involves a so‐called GTP cycle
(Figure 2). G‐proteins are heterotrimers and one of their subunits, Gα, has a binding site for guanosine nucleotide
(this gives G‐proteins their name). In an inactive G‐protein, this site is occupied by guanosine diphosphate (GDP).
Upon G‐protein activation by an agonist‐bound receptor, GDP is replaced by GTP from the cytoplasm, which leads
to the dissociation of Gα‐subunit from the Gβ and Gγ subunits (together referred to as Gβγ). The G‐protein splits
into two parts, which then activate downstream effectors. If the G‐protein uncouples from the receptor, the
receptor quickly returns to its inactive “low‐affinity” state.23 Eventual hydrolysis of GTP to GDP in the Gα subunit
lets the G‐protein reassemble and bind to the receptor again, which closes the cycle.24
Therefore, the GTP cycle acts as a negative‐feedback loop, promoting G‐protein decoupling from the receptors
and their (temporary) conversion into the low‐affinity state after agonist binding. Excess GTP shifts the equilibrium
toward complete dissociation of G‐proteins from the receptors.
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2.2 | Oligomerization‐dependent high‐affinity state
The growing amount of evidence on GPCR oligomerization in cultured cells and living tissues 25 and on the
pharmacological relevance of such oligomerization (see Ferre et al26 for review) has given rise to the concept of
oligomerization‐dependent high‐affinity state. When the agonist interacts with a receptor oligomer, occupying and
activating a single receptor unit within it, conformational changes in this receptor influence the conformation of
other receptors within the same oligomer and decrease their affinity for other agonist molecules (Figure 3). In other
words, separation into high‐ and low‐affinity states is caused by negative cooperativity effects of the agonist
binding to oligomerized receptors.27
Receptor oligomerization is arguably mainly relevant for the explanation of the interplay between signaling
pathways of different receptors26: interaction between oligomer subunits is conceptually simpler than interference
of downstream cascades. However, among data from radioligand binding studies there are also some results that
could be explained better by oligomerization than by G‐protein coupling, such as: (i) GTP‐insensitive high‐affinity
agonist binding to dopamine D3 and serotonin 5‐HT2A receptors,28,29 (ii) detection of high‐ and low‐affinity states of
F IGURE 2 GPCR activation (left circuit, open arrows) and GTP cycle (right circuit, solid arrows). As in Figure 1,
the agonist is represented by a triangle, the G‐protein by an ellipse and the receptor by a sinusoid line. The center
of the figure shows the “ternary complex” consisting of agonist, receptor and G‐protein. GPCR, G‐protein‐coupled
receptor; GTP, guanosine triphosphate
F IGURE 3 Oligomerization‐dependent high‐affinity state. In this schematic representation, the receptors are drawn as
homodimers. Most higher order G‐protein‐coupled receptor complexes are homodimers, heterodimers or tetramers
consisting of two different homodimers. The high‐affinity state of the receptor is pictured as a sinusoid, the low‐affinity
state as a compressed sinusoid, and the agonist as a triangle is pictured as a compressed sinusoid and the agonist as a
triangle
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adenosine A2A receptors by antagonist ligands,
30 and (iii) detection of several (more than two) binding sites with
different affinities to agonists in the muscarinic M2 receptor population.
31
If there is cooperativity between receptor‐agonist and receptor‐receptor interaction, agonist binding might
influence the degree of receptor oligomerization. Some studies indeed report such phenomena32,33 but, in general,
experimental data on the relationship between ligand binding and oligomerization are contradictory both in terms
of whether ligand binding really promotes formation or dissociation of oligomers and whether this action is
correlated with intrinsic activity (see Cottet et al34,35 for review).
2.3 | Influence of agonist binding on the high‐affinity state
In both G‐protein coupling and oligomerization‐dependent models of high‐affinity state, agonist binding to the
receptor influences receptor interaction with other molecules and thus can alter the relative abundance of the
high‐affinity state.
2.3.1 | G‐protein‐dependent high‐affinity state
Under conditions where no feedback loops are present, as is the case with in vitro binding studies with nonliving
material like membrane homogenates and tissue slices, the relationship between agonist concentration and percentage
of receptors in the high‐affinity state at equilibrium is straightforward. In the absence of GTP, agonist binding can only
increase G‐protein recruitment. Therefore, increasing agonist concentration will make the percentage of receptors in
the “G‐protein‐dependent” high‐affinity state grow from some “floor” value (see Section 2.5) to the “ceiling” value
determined by receptor‐G‐protein stoichiometry in the system (100% if the number of available G‐proteins is greater
than or equal to the number of receptors). On the other hand, in the presence of excess GTP and negligible GTP
hydrolysis, all G‐proteins activated by agonist‐bound receptors will be dissociated and uncoupled from the receptors,
so at any agonist concentration, there will be no discernible high‐affinity state.
In living cells and tissues, however, the GTP cycle plays the role of a negative‐feedback loop, which counteracts
excess high‐to‐low or low‐to‐high conversion of affinity states caused by the agonist. Depending on the combination
of concentrations and kinetic rates, either G‐protein‐recruiting or G‐protein‐dissociating effects of an agonist can
become dominant. Indeed, mathematical simulations of GPCR signaling have demonstrated the possibility of both
agonist‐induced increase and decrease in the relative abundance of the G‐protein‐dependent high‐affinity state.22
2.3.2 | Oligomerization‐dependent high‐affinity state
Negative cooperativity in agonist binding to oligomerized receptors implies that increasing agonist concentration
will bring more and more receptors into “low‐affinity state.” The percentage of receptors in the high‐affinity state,
equal to 100% in the absence of agonist, will decrease to 100%/N (N is the average number of receptors per
oligomer) when the agonist occupies one receptor unit in each oligomer, converting all the other units to low‐
affinity state. When agonist concentration raises so high that agonists start to occupy receptors in the low‐affinity
state, the relative abundance of the high‐affinity state will fall even lower. There are no well described and widely
accepted feedback loops for the oligomerization‐dependent model of the high‐affinity state.
2.4 | Agonist‐induced receptor internalization
Activation of GPCRs by agonists promotes not only G‐protein binding to them but also their phosphorylation by
G‐protein‐coupled receptor kinase (GRK) and internalization mediated by β‐arrestins.36 This provides an extra
pathway through which the agonist can influence the relative abundance of the high‐affinity state. Internalized
receptors are decoupled from G‐proteins (coupled to β‐arrestins instead) and removed from the cell surface to
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intracellular compartments, where the ionic environment and pH value can be different from extracellular
conditions. This makes internalized receptors less accessible (especially for hydrophilic radioligands) and possibly
also alters their affinity toward their ligands.
In vitro, β‐arrestin recruitment can happen within minutes.37,38 Internalization of dopamine D2/3 receptors was
observed within the same time frame in vivo and was shown to be dose‐dependent.39 Although it is not yet clear
whether internalization mainly happens to receptors in the low‐ or high‐affinity state,40,41 internalized dopamine
D2/3 receptors on intact cells and µ‐opioid receptors incubated in a buffer imitating endosomal medium were shown
to have decreased affinities toward their ligands.42,43
Therefore, high concentrations of an agonist can promote receptor internalization and change the number and
relative abundances of receptor subpopulations with different affinities toward imaging radioligands. On the other
hand, in internalization‐deficient β‐arrestin knockout mice, baseline binding of dopamine D2/3 agonist and
antagonist tracers was the same as in wild‐type controls.44 This may mean that at basal neurotransmitter levels
there already is an equilibrium between neurotransmitter‐induced receptor internalization and recycling.
2.5 | Relative abundance of high‐affinity state in the absence of the agonist
The oligomerization‐dependent model of the high‐affinity state implies that this is the state in which all receptors
are configured in the absence of the agonist.
For the G‐protein‐dependent high‐affinity state, its baseline relative abundance, that is, the degree to which
G‐proteins interact with the receptors in the absence of agonist is a matter of debate.45,46 One extreme view, called
collision coupling (Figure 4A), states that in living cells G‐proteins are not normally bound to the receptors but
instead interact with them transiently when receptors become activated.47 Another extreme view (Figure 4B)
states that G‐proteins are always bound (precoupled) to the receptors and do not decouple even after activation,
which happens through structural rearrangement of the G‐protein rather than through dissociation.48–50
On the one hand, collision coupling provides a straightforward interpretation of differences in intrinsic activities
of the agonists: agonist efficacy is related to the number of different G‐proteins that an agonist‐bound receptor can
bind and activate per unit of time. Decoupling of G‐proteins from the receptors upon activation explains the
disappearance of the high‐affinity state upon GTP addition in membrane homogenates. On the other hand,
receptors and G‐proteins are known to be coisolated by immunoprecipitation and bioluminescence resonance
energy transfer/fluorescence resonance energy transfer (BRET/FRET) experiments with mutated proteins
incorporating fluorescent or bioluminescent probe demonstrate close contact between receptors and G‐proteins
in the absence of agonists.45 Moreover, in BRET studies with α2 adrenergic and δ‐opioid receptors, these receptors
were found to interact with G‐proteins both before and after activation by agonist.49,50
F IGURE 4 Two extreme modes of receptor‐G‐protein interaction. The agonist is represented by a triangle, the
receptor by a sinusoid line and the G‐protein by an ellipse. A, In the collision coupling model, G‐proteins do not stably
interact with receptors but agonist action on the receptor promotes G‐protein recruitment to and activation by the
receptors, which results in the dissociation of G‐proteins. B, In the precoupling model, G‐proteins are stably bound to the
receptors and rearrange their structures upon activation instead of dissociating. GDP, guanosine diphosphate; GTP,
guanosine triphosphate
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A middle ground between the extreme views is, of course, possible, where some G‐proteins are bound to
receptors at baseline but decoupled upon activation, or where G‐proteins are uncoupled at baseline but become
bound to receptors upon activation. Moreover, BRET and FRET experiments image the whole population of the
receptors, so constant presence of a RET signal, while showing that a fraction of receptors are engaged with
G‐proteins, does not exclude the possibility of a rapid turnover of G‐proteins with which these receptors interact.
2.6 | Summary
The existence of high‐ and low‐affinity states of GPCRs is commonly thought to be due to receptor interaction with
G‐proteins. Being a part of the canonical GPCR signaling cascade, the receptor‐G‐protein coupling is directly
related to the pharmacological activity of the agonists.
GPCR oligomerization (both homo and hetero), with negative cooperativity in agonist binding within the
oligomer, can be an alternative mechanism leading to the formation of receptor subpopulations with different
affinities for the agonist. It is plausible that at least for some GPCRs, oligomerization can contribute to the splitting
of receptors into high‐ and low‐affinity states instead of, or in addition to, G‐protein coupling.
Both models of high‐affinity state imply that agonists preferentially bind to receptors that are almost ready to launch
the signaling cascade, although in the oligomerization model it is so just because agonist binding makes unoccupied
receptors “less ready.”Moreover, agonist binding can influence the relative abundance of the high‐affinity state, potentially
promoting its formation or disintegration and launching receptor internalization in intact cells and living tissues. Such
influence is most directly demonstrated for the G‐protein‐dependent model of the high‐affinity state.
3 | EXPECTED ADVANTAGES AND DISADVANTAGES OF AGONIST
TRACERS RELATIVE TO ANTAGONIST TRACERS
From the notion that agonists preferentially bind to a high‐affinity functional subset of receptors one can logically
infer a number of applications in which agonist tracers should be superior, in theory, to antagonist tracers. Note
that proposed advantages of agonist tracers mentioned below hold independently of whether the high‐affinity state
is G‐protein‐dependent or oligomerization‐dependent.
3.1 | Applications where agonist tracers have comparative advantage over antagonist
tracers
3.1.1 | Measurement of synaptic neurotransmission
An endogenous neurotransmitter is an agonist by definition, so it competes with the agonist tracer for the same
subset of receptors—receptors configured in high‐affinity state—while an antagonist tracer also binds to receptors
in the low‐affinity state that are “ignored” by the neurotransmitter except at very high concentrations. This means
that a change in the concentration of neurotransmitter of a given magnitude will lead to greater change in agonist
tracer binding compared with antagonist tracer binding (Figure 5).
For some receptor families (eg, serotonin 5‐HT1A and 5‐HT2A receptors), all available antagonist tracers appear to be
insensitive to alterations of endogenous neurotransmitter levels.51 As agonist tracers are supposed to be more sensitive
than antagonist tracers to endogenous neurotransmitter competition, developing agonist ligands is considered a promising
way to obtain a tool for the measurement of synaptic neurotransmission via these receptors.52
3.1.2 | Studies of (pathological) alterations in receptor availability
In Section 1, a few examples were given of how alterations of the percentage of receptors configured in the high‐
affinity state can accompany the disease. Since the high‐affinity state is the active form of the receptor involved in
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signaling and may be primarily affected by the disease, the abundance of the high‐affinity state could be a more
meaningful biomarker than the total receptor density. Agonist tracers should then be a convenient tool for
pinpointing alterations of the availability of receptors configured in the high‐affinity state in disease.
The results of some in vitro experiments with agonist and antagonist radioligands have supported the
hypothesis that agonist tracers are superior to antagonists in detecting pathological changes in neuroreceptor
availability. In vitro binding of the 5‐HT1A agonists [18F]F15599 and [18F]F13640 but not of the antagonist [18F]
MPPF, in postmortem brain sections of Alzheimer’s patients was decreased compared with control brains.53,54 In
unilateral 6‐hydroxydopamine‐induced lesions of the rat brain (exhibiting dopaminergic neurodegeneration similar
to Parkinson’s disease in humans, where upregulation of Rhigh is hypothesized), the ex vivo binding of dopamine D2/
3 agonist [
3H]NPA was changed to a greater extent than the in vitro binding of D2/3 antagonist [
3H]raclopride.55
3.1.3 | Measurement of agonist drug occupancy
Many drugs owe their effect to their agonist activity at one or more kinds of receptors. For instance, many
antiparkinsonian drugs are D2/3 agonists
56; muscarinic receptor agonists like milameline were tried as treatment of
Alzheimer’s disease57; the mechanism of action of antipsychotics may include not only D2/3 antagonism but also 5‐HT1A‐
agonism58,59; the active metabolite of clozapine (also an atypical antipsychotic) acts as an agonist at muscarinic M1
receptors60; opiate agonists are widely used as analgesics or antitussives and for treating diarrhea and opiate abuse.61
Increased sensitivity of agonist tracers to displacement by agonist drugs may be an advantage in occupancy studies:
the opioid receptor antagonist [11C]diprenorphine failed to detect receptor occupancy by clinically relevant doses of opioid
agonists.62,63 However, no studies have so far been published, where the sensitivity of an agonist and an antagonist opioid
receptor tracer with equal subtype‐selectivity to displacement by an agonist drug was compared head‐to‐head.
Agonist tracers can also complement antagonist tracers in the investigations of the affinity‐state preference of
new drugs. The sensitivities of agonist and antagonist tracers to the displacement by the drug can be compared:
drugs preferring the high‐affinity state will displace the agonist tracer more readily, while drugs not distinguishing
between affinity states will show no difference in displacement efficacy. Two studies attempting this approach have
F IGURE 5 Greater sensitivity of agonist tracers to displacement (“challenge”) by neurotransmitter. Agonist
tracers primarily bind to the receptors configured in the high‐affinity state (ie, coupled to G‐proteins), as do
neurotransmitters. Therefore, the same change in receptor occupancy by the neurotransmitter displaces a greater
fraction of bound agonist tracer (A) than of bound antagonist tracer (B). In this schematic diagram, the endogenous
neurotransmitter is pictured as a circle, the agonist ligand as a triangle, the antagonist ligand as a diamond, the
G‐protein as an ellipse, and the receptor as a sinusoid line
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been published64,65 but both reported equal displacement of agonist and antagonist tracers by the drug, which can
be interpreted in two ways: either the tested drugs were ideal antagonists or the hypothesis of greater agonist
tracer displacement by agonist drug does not hold.
3.2 | Intrinsic shortcomings of agonist tracers
Though the preference for the high‐affinity state makes agonist tracers potentially superior to antagonists in
certain imaging applications, it also results in a number of specific difficulties associated with the development and
use of agonist tracers.
3.2.1 | Lower signal‐to‐noise ratios
The signal‐to‐noise ratio of a PET tracer is proportional to the density of receptors the tracer binds to in the brain
(Bavail) and to the tracer’s affinity toward these receptors (1/Kd). The density of receptors configured in the high‐
affinity state (and thus recognized by agonist tracers) is by definition lower than the total receptor density.
Moreover, estimates of agonist affinity toward the high‐affinity state, acquired in membrane homogenates in
vitro, may be systematically higher than the actual affinity in vivo. The reason why it may be so is the negative‐
feedback between agonist‐receptor and receptor‐G‐protein binding in the GTP cycle (see Section 2.3), which is part
of the G‐protein‐dependent model of the high‐affinity state. Indeed, GTP depletion was shown to increase the
affinity of agonist but not antagonist ligands to opioid receptors in cultured cells.66 Therefore, affinity and
nonspecific binding requirements for agonist tracers are stricter than for antagonists.
3.2.2 | Greater likelihood of unwanted pharmacological effects
As agonist tracers preferentially bind to the functional subpopulation of the receptors, they may induce significant
physiological responses at a rather low dose, which can distort the experimental results and cause discomfort to
the patients.
Indeed, staying below the pharmacological dose range is a concern in opioid receptor imaging with agonist
tracers.67–69 It was also reported as a potential concern in serotonin 5‐HT1A receptor imaging with the agonist [11C]
CUMI‐101,70 even though first tests of the same compound in humans showed no adverse effects.71 Exceeding the
pharmacological threshold is especially easy with tracers with low specific radioactivity and a related high injected
mass of the radioligand. The risk of low specific radioactivity is increased when labeling chemistry is complex. For
instance, the dopamine D2/3 receptor agonist [
11C](+)PHNO was originally labeled via a four‐step route, resulting in
a relatively low specific radioactivity.72 As a consequence, a high incidence of nausea (emesis is a typical effect of
D2 agonism) was reported in patients injected with [
11C](+)PHNO,73 and it was later found that [11C](+)PHNO
human PET studies had frequently been performed under nontracer conditions.74
4 | EXISTING PET AGONIST TRACERS FOR GPCR IMAGING IN THE
CENTRAL NERVOUS SYSTEM
The greatest number of agonist PET tracers has been developed for the imaging of dopamine D2/3 receptors (see
75
for a review). Tracer development efforts in the last two decades have yielded a number of agonist radioligands for
other receptors as well. The most promising agonist tracers developed for PET imaging of neuroreceptors are
presented in Table 1, Figure 6 and Figure 7.
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4.1 | Definition and properties of an agonist tracer
An agonist tracer is usually defined as “a radiolabeled analog of a ligand with agonist activity.” There are many ways
to confirm and measure the degree of agonist activity: behavioral or ex vivo studies examining the physiological
effect of the drug, functional in vitro assays measuring the levels of certain secondary messengers, or the recruiting
of proteins involved in signaling cascades to the receptors.
Because the intrinsic activity of a ligand is known to be correlated with the ratio of its affinities to the high‐
and low‐affinity receptor states,18,19 it seems evident that agonists will preferentially bind to the high‐affinity
state. However, agonism does not necessarily imply preferential binding to receptor‐G‐protein complexes, since
noncanonical signaling pathways do exist. One example is cariprazine, a drug which was recently labeled with
carbon‐11 and evaluated as a dopamine D2/3 receptor PET tracer. This compound showed partial D2/3 agonist
activity in secondary messenger assays but did not recruit G‐proteins in vitro.176–178 Observations of G‐protein
recruitment may also differ between in vitro setups. For instance, [11C]CUMI‐101, a tracer for serotonin 5‐HT1A
receptors, was defined as an agonist based on the [35S]GTPyS assay (indirect measurement of G‐protein
F IGURE 6 Chemical structures of agonist radioligands for dopaminergic receptors (see also Table 1). The
position of the radionuclide in each molecule is indicated by an asterisk
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recruiting to receptors) in membrane homogenates from cell cultures expressing recombinant human receptors
but was later found to act as an antagonist when the same assay was done in primate and rat brain
homogenates.118,119
Therefore, the most certain proof of the agonist radioligand’s in vitro preference to the high‐affinity state is
directly demonstrating that it recognizes high‐ and low‐affinity states of its receptor in natural tissue or in
transfected cell culture. It is worth noting that for some agonist tracers, preferential in vitro binding to Rhigh was
demonstrated only after the tracer had been evaluated in vivo (compare 105 and 28), while for some other
radioligands the capability to discern affinity states in vitro was not assessed at all.80,135
F IGURE 7 Chemical structures of agonist radioligands for serotonin, opioid, and muscarinic receptors (see also
Table 1). [11C]PEO is not shown; its structure can be found in Van Waarde et al.175 The position of the radionuclide
in each molecule is indicated by an asterisk
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4.2 | In vivo evaluation of a PET neuroreceptor tracer
Characteristics desirable for a PET tracer for brain imaging include the ability to pass the blood‐brain‐barrier, a low
degree of metabolism, a high contrast between target (specific) and nontarget (nonspecific) binding, and
pharmacokinetics that can be reliably quantified from a 60 to 90 minute‐long PET scan (see 179–181 for review). An
important aim in PET imaging is the measurement of synaptic neurotransmission. For this reason, neuroreceptor
tracers are tested for the sensitivity of their binding to changes of endogenous neurotransmitter levels, and
agonists are supposed to be more sensitive than antagonists.
Neuroreceptor tracers are usually evaluated in rodents or non‐human primates before being moved to
human studies. In non‐human primates, one can investigate the binding of the tracers with high spatial detail
using clinical PET cameras. Evaluation in rodents is cheaper and enables the use of more invasive methods but
interspecies differences in rodent, primate, and human physiology can be a confounding factor. In addition, the
small size of rodents forces the researchers to use dedicated nonclinical “micro‐PET” cameras and does not
permit to reliably image minor brain structures. To strike the right balance between controllability of the
experimental conditions and image quality, tracers are sometimes evaluated in (relatively) large mammals, such
as cats or pigs.
4.3 | Availability of agonist PET neuroreceptor tracers
Agonist PET tracers can be divided into three categories (see Table 1). The first category includes radioligands that
have reached the stage of in vivo evaluation in humans. The dopamine D2/3 ligands [
11C](+)PHNO, [11C]NPA, and
[11C]MNPA, the serotonin 5‐HT1A ligand [11C]CUMI‐101, the serotonin 5‐HT2A ligand [11C]CIMBI‐36, the κ‐opioid
ligand [11C]GR103545, the µ‐opioid ligand [11C]carfentanil, and the muscarinic M2 receptor agonist [18F]FP‐TZTP
fall into this category. The binding of most of these ligands has been shown to be sensitive to changes of
endogenous neurotransmitter levels, although for [11C]CIMBI‐36 and [11C]CUMI‐101 the acquired results have
been conflicting, and the sensitivity of [11C]GR103545 to endogenous opioids has not yet been evaluated. Many
ligands from category one are used in PET imaging for other reasons than their agonist properties. [11C](+)PHNO,
for example, is frequently selected as a tracer because it binds preferentially (though not selectively) to dopamine
D3 receptors, and its preference for this subtype is higher than that of dopamine D2/3 antagonist ligands like [
11C]
raclopride.95 [11C]CUMI‐101 is used in clinical studies,182,183 not because of its ability to image the high‐affinity
state of serotonin 5‐HT1A receptors (which is actually under doubt—see below) but because of its high subtype‐
selectivity and imaging contrast. [11C]carfentanil and [18F]TZTP are the only tracers available for µ‐opioid and
muscarinic M1 receptors, so in their case, there are no antagonist tracers with which they could be compared head‐
to‐head.
The second category contains radioligands that have not (yet) been tested in humans but have been
evaluated in non‐human primates. The dopamine D1/5 ligand (S)[11C]NNC 01‐0259, the dopamine D2/3 ligand
[18F]MCL‐524, the dopamine D2 ligand [11C]SV‐III‐130, the dopamine D3 ligand [18F]LS‐3‐134, the serotonin
5‐HT1A ligands [18F]F13714 and [18F]F13640, and the muscarinic M1 ligand [11C]LSN3172176 belong to this
group. The binding of the dopamine D2, D3, and D2/3 ligands from this category has been shown to be sensitive
to changes of endogenous neurotransmitter levels but for the dopamine D1/5 the results were negative, and
there are currently no D1/5 agonists or antagonists that would be sensitive to endogenous dopamine levels.
Sensitivity of [18F]F13714, [18F]F13640, and [11C]LSN3172176 to endogenous serotonin/acetylcholine has not
yet been evaluated in primates, although [18F]F13640 was sensitive to serotonin levels in rats. Some of these
compounds were radiolabeled with 18F or 18F‐versions of previously developed 11C‐tracers because the longer
half‐life of fluorine‐18 makes an imaging agent more suitable for wide‐scale clinical use. [18F]sufentanil has
been created as a longer half‐life alternative to [11C]carfentanil but was not further developed.184
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The third and last category contains tracers that have only been evaluated in rodents. The dopamine D1/5 ligand
(S)(+)[11C]SKF82957, the dopamine D3 ligand [
18F]7‐OH‐FHXPAT, the µ/κ‐opioid agonist [11C]PEO, and the
muscarinic agonist [11C]AF‐150(S) fit in this category.
Binding of (S)(+)[11C]SKF82957 is known to be insensitive to changes of endogenous neurotransmitter levels.
Available data for [11C]AF‐150(S) in this regard are inconclusive, and for other tracers from this category sensitivity
to endogenous neurotransmitter levels has not yet been evaluated.
In the process of tracer development, some agonist tracers were found to have issues that hamper their
routine application. Two radioligands for dopamine D1/5 receptors, (R)‐[11C]SKF82957 and (S)‐[11C]N‐methyl‐
NNC 01‐0259,81,185 are converted to lipophilic radioactive metabolites that penetrate into the brain and can
confound the interpretation of imaging results, though this can be remedied by inhibiting the activity of the
enzyme catechol‐O‐methyl transferase.77 Another D1/5 agonist, [11C]SKF75670, was originally developed
together with [11C]SKF82957 but was abandoned because of inferior signal‐to‐noise ratios. Since it is
structurally very similar to [11C]SKF82957, it may show the same unfavorable in vivo metabolism.78 The
development of (S)‐[11C]N‐methyl‐NNC 01‐0259 was halted since tests examining its sensitivity to endogenous
dopamine levels yielded a negative result.80 The D3‐selective agonist tracer [18F]LS‐3‐134 was shown to
specifically bind to D3 receptors in monkey brain but specific binding was only measurable under dopamine
depletion conditions.115 The muscarinic M1 receptor tracer [
11C]AF‐150(S) showed both specific binding and
sensitivity to endogenous acetylcholine levels in the rat brain but the low signal‐to‐noise ratios of this ligand
cast doubt on its suitability for further research.165,166
To demonstrate the preferential binding of agonist tracers to receptor high‐affinity state, a head‐to‐head
comparison with reference tracers binding to all receptors (ie, antagonist tracers) is required. For D1/5, D2/3,
5‐HT1A, and 5‐HT2A agonist tracers counterpart antagonist tracers are available, which possess matching
pharmacological selectivity (ie, bind with similar relative affinities to the same receptor subtypes within the
relevant region of interest as their “corresponding” agonist tracers) and, in case of D2/3 and 5‐HT2A ligands,
sensitivity to endogenous neurotransmitter levels.51,186–188 The same is true for the κ‐opioid agonist [11C]
GR103545, which was developed along with its antagonist counterpart [11C]LY2795050,189 and for the µ/κ‐
opioid agonist [11C]PEO, which can be used in conjunction with the µ‐partial agonist and κ‐antagonist [11C]
buprenorphine.159 For the µ‐opioid agonist [11C]carfentanil, the M2 agonist [18F]FP‐TZTP and M1 agonists [18F]
AF‐150(S) and [11C]LSN3172176 there are no suitable antagonist counterparts.175,190 In theory, non‐subtype‐
selective radioactive antagonists might be used in head‐to‐head comparisons with radioactive agonists if
receptors to which the antagonist, but not the agonist, binds are fully blocked with a nonradioactive drug, but
the feasibility of that approach is questionable because of the possible pharmacological effects of such
blockade.
In conclusion, agonist tracers for PET imaging of dopamine D2/3, serotonin 5‐HT1A and 5‐HT2A, µ and κ‐opioid,
and M2 muscarinic receptors are available. Agonist tracers for dopamine D1/5 and muscarinic M1 receptors have
issues that make their use for PET imaging problematic. Preference for the high‐affinity state in vitro has only been
directly demonstrated for D1/5 and D2/3 tracers, some 5‐HT1A tracers and the M1 tracer [18F]AF‐150(S). Agonist
tracers for D2/3, 5‐HT1A, 5‐HT2A, and κ‐opioid receptors can be matched with antagonist tracers binding to the
same receptors for head‐to‐head comparisons.
5 | PROVING THE EXISTENCE OF THE HIGH ‐AFFINITY STATE IN VIVO
5.1 | Outcome measures of in vivo experiments
In vivo experiments with neuroreceptor radioligands measure the availability of the receptors and changes in this
availability in response to alterations of endogenous neurotransmitter levels or administration of exogenous drugs.
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Binding potentials (BPs) and target/nontarget ratios are “raw” measures representing receptor availability, which
can later be recalculated to receptor densities or occupancies.
5.1.1 | Binding potentials
The typical outcome measure of in vivo imaging experiments is the BP. This parameter is defined as the product of
the density of binding sites (Bmax) and the affinity of the radioligand for these sites (inverse of the dissociation
constant, 1/Kd). BP is equal to the ratio of the concentrations of specifically bound and free ligand in the tissue of
interest at equilibrium, provided that the administered dose of radioligand is sufficiently low (see the Appendix for
more explanation). BP is estimated by fitting a kinetic model to measured time‐activity curves. Time‐dependent
radioactivity in the region of interest and a reference region in the brain can be measured by PET imaging, and
plasma radioactivity can be determined by blood sampling.191 Note that in vivo not all receptors may be available
for binding, as they can be internalized, converted to low‐affinity state (for an agonist) or occupied by
neurotransmitter, so in the in vivo context the term Bavail is more suitable than Bmax.
Given the difficulty of determining the true concentration of the free ligand in the living tissue, other
concentrations proportional to free ligand concentration in tissue are substituted in its place. Specifically, bound
concentration is related to free plasma concentration (BPF), total plasma concentration (BPP), or “nondisplaceable”
concentration (BPND), that is, the total concentration of free and nonspecifically bound ligand in the tissue.
192 It is
reasonable to assume that free ligand concentrations in the plasma and in the interstitial liquid of the brain tissue
are equal at equilibrium, so BPF can be considered the “true” BP.
5.1.2 | Target/nontarget ratios
When regions of interest are small relative to PET camera resolution (ie, subsections of rodent brain) it is often
hard to obtain a reliable time‐activity curve with high temporal resolution. Also, in situations when a lot of
experimental conditions have to be tested and compared, it is often infeasible to obtain time‐activity curves by PET
or to sacrifice large groups of animals at different time points. In these situations, one can take advantage of the
“pseudoequilibrium” state when the concentration ratios between receptor‐rich and receptor‐free tissues remain
constant even as absolute concentrations are changing. For a typical neuroreceptor ligand, one can reasonably
expect the pseudoequilibrium state to be reached within half an hour after injection. Once the time range in which
the pseudoequilibrium exists is validated, specific binding can be estimated from tissue concentrations at a single
time point within this time range. Such concentrations can be obtained by ex vivo dissection and radioactivity
counting or from a static PET scan. Target/nontarget concentration ratios can be used as is or be recalculated to
specific binding ratios (SBRs):
=   − = −T TSBR NT
NT NT
1.
where T and NT are radioligand concentrations in receptor‐rich (“target”) and receptor‐poor (“nontarget”) regions
of interest. In the absence of specific binding, SBR = 0, while T/NT = 1.
“Raw” specific binding, that is, the difference between radioligand concentrations in receptor‐poor and
receptor‐rich regions can also be used as an outcome measure. However, when specific ligand binding is not
normalized to the nonspecific binding at the same time point, its value is prone to intrasubject variations in
pharmacokinetics. Therefore, the use of binding ratios is preferred.
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5.1.3 | Available receptor density
Available receptor density (Bavail) can be estimated in a saturation experiment. Specific binding of a radioligand
is determined by two parameters: the density of binding sites in the region of interest (Bavail) and the affinity of
the radioligand toward these receptors (1/Kd). To independently estimate these two parameters, bound and free
radioligand concentrations at equilibrium have to be estimated at least at two different injected doses
(for radiotracers, injected dose is usually varied by changing molar radioactivity). Bound concentration can be
estimated from a difference in equilibrium tracer concentrations between the target and nontarget regions,
while free concentration can be back‐calculated from the binding potential (see Appendix). Bavail can then be
quantified by regression analysis. In PET imaging, the regression is often performed on “linearized” binding data:
binding potential is plotted against absolute specific binding (Scatchard plot). Scatchard plot requires a simple
linear regression and is therefore straightforward but also bias‐prone, as the X and Y axes are not independent
of each other. Alternatively, Bavail can be estimated by nonlinear regression of the binding curve (bound vs free
concentration plot). For in vitro assays, where free and bound ligand concentrations can be independently
estimated, nonlinear regression is the gold standard. However, for in vivo experiments the Scatchard plot has
remained popular.
5.1.4 | Receptor occupancy
Displacement of a tracer from its receptors by a competing ligand decreases the binding potential of the tracer.
Receptor occupancy can be calculated as the change in binding potential or target‐nontarget ratio after drug
administration, relative to baseline. The same holds for the occupancy of the receptors by endogenous
neurotransmitter, when drugs stimulating neurotransmitter release or depletion are administered.
5.2 | Experimental paradigms used to demonstrate the existence of high‐affinity state
in vivo
To demonstrate that agonist tracers preferentially bind to a certain “high‐affinity” subset of receptors in vivo three
approaches have been used (summarized in Table 2). One approach is to directly measure the available binding site
densities for agonist and antagonist tracers and demonstrate that the binding site density available to the agonist is
lower. Another is to infer the ratio of high‐affinity binding site density to total binding site density from the results
of experiments where tracers compete for binding to the receptors with unlabeled ligands. A third approach is to
demonstrate that agonist, but not antagonist, binding can be influenced by manipulations of receptor‐G‐protein
coupling.
It is important to emphasize that to compare agonist and antagonist tracers with each other their
pharmacological selectivity profiles (ie, relative binding affinities toward different receptor subtypes) should
be identical within the region of interest used for comparison. Otherwise, any detected difference in binding
behavior could be attributed to the relative preference of one of the tracers toward a certain receptor
subtype.
In principle, all experiments described below can be performed not only with PET tracers labeled with
short‐lived positron‐emitting isotopes but also with radioligands labeled with long‐lived isotopes such as
tritium (3H). On the one hand, this makes the experimental paradigm nontranslatable to the clinical setup. On
the other hand, this enables the use of elegant approaches like the double‐tracer study, where radioligands
labeled with short‐lived (eg, 11C) and long‐lived (eg, 3H) isotopes are compared head‐to‐head in the same
group of animals.194,196
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5.2.1 | Approach 1: comparing binding site densities
Saturation study
As explained above, a minimum of two different radioligand doses needs to be tested to estimate binding site
density (Bavail). More doses will add precision and can reveal potential cooperativity effects or the presence of
multiple binding sites with different affinities (eg, receptor affinity states), provided that radioligand binding to all
these sites is distinguishable from nonspecific binding. However, published PET studies comparing binding site
densities of agonist and antagonist tracers were restricted to two doses.90,193 Another study used single time point
SBRs as outcome measure and built saturation curves based on 9 to 10 data points.122
In two‐dose PET studies aimed at quantifying Bavail, the low dose corresponds to the minimum amount of
radioligand that can be injected, that is, the “tracer dose,” which should occupy less than or equal to 10% of the
receptor population in the region of interest. The high‐dose is chosen to occupy about two‐thirds of that
population.90,193
Extracting density values from true binding potential measurements
It should be noted that performing a saturation assay with agonist radioligands can lead to unwanted and
dangerous pharmacological effects, especially in the case of opioid ligands.68,69
In a head‐to‐head comparison of 5‐HT1A agonist and antagonist tracers, Kumar et al70 attempted to circumvent
this problem by comparing the “true” binding potentials (BPF) for the two tracers at low injected dose instead of
performing a second high‐dose scan to independently measure Bavail and Kd. Given that BPF = Bavail/Kd, Bavail can
arguably be calculated from the BPF value using in vitro Kd value for the corresponding tracer. However, there are
two problems with this approach. First, to calculate BPF, one needs to obtain an arterial input curve and free
fraction in plasma for the investigated radioligand, in addition to the time‐activity curve for the region of interest.
Such a large amount of input data makes BPF prone to experimental error and bias. Second, the in vivo Kd of the
radioligand is not necessarily equal to the in vitro Kd, especially if the latter is measured for receptors from a
different animal species or in transfected cells.
Studying correlation between regional binding of agonist and antagonist
Binding potentials or target/nontarget ratios for an agonist tracer in various brain regions can be plotted against
the corresponding measurements for an antagonist tracer, to examine their correlation. Such a plot may provide
insight into the relationship between the densities of available binding sites for agonist and antagonist tracers while
staying below the “tracer” threshold. If agonist binding in a certain brain region lies above the main trend on the
correlation graph, it suggests that the relative abundance of receptors in the high‐affinity state in this region is
higher than average, and vice versa.
This approach, however, has many limitations. If the relative abundance of the high‐affinity state is drastically
different in each region, the correlation graph will be meaningless: there will be no main trend to pinpoint
deviations from. If the relative abundance of the high‐affinity state is the same in all regions, the correlation graph
will be a straight line, revealing no differences in agonist and antagonist binding and thus no evidence in favor of
the existence of the high‐affinity state. Therefore, analysis of the correlation between agonist and antagonist
binding cannot be the sole method of looking for the existence of high‐affinity state but can be an extra piece of
data analysis in experiments based on other paradigms.
Studying agonist binding in disorders presumably caused by high‐affinity state dysregulation
In vitro experiments in membrane homogenates suggest that some neuropsychiatric disorders are accompanied by
alterations in the relative abundance of the high‐affinity state in a given receptor population, while changes in
overall receptor density relative to the healthy condition are either absent or much less pronounced. One example
is animal models of psychosis where the high‐affinity state of dopamine D2/3 receptors is upregulated.14,201
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Therefore, another way to demonstrate the existence of a high‐affinity state in vivo is to show that its
upregulation (or downregulation) can be noninvasively detected by agonist tracers. If the relative abundance of the
high‐affinity state is altered but the overall receptor density remains (relatively) constant, the binding of the agonist
but not of the antagonist tracer will be different in the diseased state relative to the healthy state. Ratios of BP or
SBR values for agonist and antagonist tracers can be used as outcome measures to normalize for possible
concomitant alterations in total receptor density.202
In this paradigm, the binding of each tracer only has to be assessed at a low and pharmacologically inactive
dose. However, one has to demonstrate that the relative abundance of high‐affinity state really differs between
healthy and diseased states, using experimental approaches other than PET (typically, in vitro assays). Moreover, in
the diseased state, alteration of the relative abundance of the high‐affinity state may be accompanied by alterations
in other parameters relevant for radioligand binding. For instance, changes in baseline neurotransmitter levels also
differentially affect the binding of agonist and antagonist tracers (agonist binding is changed to a greater extent).
Concomitant changes in several parameters pressing agonist tracer binding in different directions can offset each
other, leading to little or no change in overall receptor availability to the agonist tracer compared with the healthy
state.
5.2.2 | Approach 2: studying tracer vulnerability to displacement by an unlabeled
competitor
One important difference between tracer‐drug competition experiments in vitro and in vivo is that in the latter
case the concentration of both tracer and drug at the receptors is not constant. While for the radioligand a true
equilibrium between its concentrations in blood and brain tissue can be achieved by using bolus‐plus‐infusion
injection scheme, the same is virtually infeasible for the unlabeled drug (tissue concentrations of which are much
harder to monitor). Nevertheless, one can usually safely assume that the pharmacokinetics of the competing drug
are dose‐linear within the investigated dose range, so the degree of displacement of the tracer by the drug is also
dose‐linear.
Building in vivo displacement curves
In vitro, the high‐affinity state is detected by displacing an antagonist radioligand with ever increasing
concentrations of unlabeled agonist drug. When the remaining specific binding of the radioligand is plotted
against agonist concentrations, the displacement is shown to proceed in two phases: agonist first displaces the
radioligand from high‐affinity sites then from low‐affinity sites. The same displacement curve can be built in vivo by
plotting binding potentials or target/nontarget ratios for an antagonist tracer against an administered dose of
unlabeled agonist drug.
The advantage of this paradigm is that it does not require an agonist radioligand. Antagonist radioligands are
much more numerous than agonist radioligands, so the displacement curve paradigm is currently applicable to a
wider range of receptors than other paradigms mentioned below.
The downside, however, is that the generation of a displacement curve is a laborious undertaking. The shape of
the biphasic curve is determined by five parameters: maximum binding level (at no displacement), minimum binding
level (full displacement), agonist affinities for high‐ and low‐affinity states, and the percentage of receptors in the
investigated population configured in the high‐affinity state. This means that at least five different dose levels
(including zero) have to be used to test whether the obtained curve is monophasic or biphasic.
Therefore, studies that used the displacement curve approach typically used SBRs obtained ex vivo at a single
time point from large numbers of rodents,86,196 though the use of PET scanning in primates has also been
reported.197,198 The actual number of dose levels tested was 6 to 9 in rodent and 9 in non‐human primates.
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Comparing vulnerability to displacement by unlabeled agonist
An agonist tracer should be more vulnerable than an antagonist tracer to displacement (or “challenge”) by other
agonists because it competes with them for the same subpopulation of receptors. Displacement can be elicited by
administering an appropriate agonist drug or by stimulating endogenous neurotransmitter release.
The advantage of using exogenous agonist drugs for displacement is that these drugs can be selected to be
subtype‐specific and to only occupy the receptor population that is being imaged (or even a defined subset of this
population if the tracer binds to more than one receptor subtype).
On the other hand, manipulating neurotransmitter levels has the advantage of being “natural”: one looks at the
competition of the tracer with the endogenous ligand, the action of which on the receptors is thought to govern
the functioning of the brain [see Laruelle187 and Finnema51 for reviews]. One can also reasonably expect that
the competition will only happen at receptors that are really situated in the synapses. Moreover, neurotransmitter
levels can be both increased and decreased relative to the baseline. In the latter case, the expected result is greater
increase, rather than greater decrease, of binding for the agonist tracer. However, manipulating neurotransmitter
release has its downsides, too. First, the effect vs time relationship between the administration of the drug that
stimulates a rise or fall in endogenous neurotransmitter level and synaptic receptor occupancy is more complex
than when receptors are occupied with exogenous agonist. Second, the released neurotransmitter can act on other
receptor subtypes beyond the one being imaged. Third, some drugs used to manipulate neurotransmitter levels are
known to manipulate levels of several neurotransmitters at once (eg, amphetamine stimulates both dopamine and
norepinephrine release). The lack of selectivity regarding what neurotransmitter is manipulated and which
receptors are occupied can confound the interpretation of cause‐and‐effect relationships.
If the “tracer condition” is satisfied (radioligands occupy a negligible fraction of all receptors), the ratio of
agonist and antagonist radioligand vulnerabilities to displacement by a challenge is a constant value as long as less
than 100% of the high‐affinity state is occupied as a result of the challenge (Figure 8). Therefore, in theory, a single
dose of agonist drug or neurotransmitter level manipulator should provide enough information to compare the
vulnerability of agonist and antagonist tracers. In practice, because the actual percentage of receptors in the high‐
affinity state is unknown, several doses are often tried, resulting in occupancies of up to 100%,86,90,107,196 except in
the human studies where the maximum challenge magnitude is limited by ethical considerations.93,102
F IGURE 8 Relationship between agonist and antagonist tracer displacement (ΔBAg and ΔBAn) and the fraction
of receptors occupied by competing agonist drug or neurotransmitter. Bmax is the total receptor density available at
baseline, XH is the fraction of receptors configured in the high‐affinity state, Bocc is the amount of receptors
occupied as a result of the challenge. If Bocc < XHBmax, that is, not all high‐affinity state receptors become occupied,
the ratio of relative decreases of agonist and antagonist tracer binding is constant and equal to 1/XH
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An important limitation of the vulnerability comparison paradigm is that preference for the high‐affinity state is
not the only factor influencing the vulnerability of the radioligand to displacement by unlabeled drugs. For instance,
many preclinical in vivo tracer binding experiments are performed in anesthetized animals, and isoflurane and
ketamine anesthesia were found to increase the baseline binding of agonist D2/3 tracers, exaggerating the
vulnerability of agonist tracers relative to antagonists.109,203 The mechanism of such selective influence is unclear,
although there are reports that anesthetics interfere with receptor‐G‐protein (un)coupling 204,205 and alter
endogenous neurotransmitter levels.206,207
Furthermore, D2/3 antagonist tracers are known to differ between themselves in the sensitivity to changes in
dopamine levels.187,208 The underlying reasons can be more or less favorable binding kinetics (see Finnema
et al51,209 for discussion) or differences in affinity toward the surface and internalized receptors.210,211 Although a
head‐to‐head comparison of D2/3 agonist [11C]MNPA and D2/3 antagonist [18F]fallypride in internalization‐deficient
mice demonstrated that competition with the neurotransmitter is sufficient to explain short‐term (though not long‐
term) changes in binding for both tracers,44 this situation can be different for other receptor types.43
5.2.3 | Studying vulnerability to G‐protein uncoupling in vivo
Addition of GTP or its analogs decreases specific binding of agonist but not antagonist ligands in vitro, so
uncoupling of G‐proteins induced in vivo should lead to the same effects.
Seeman15 demonstrated that GTP addition to tissues extracted from an animal after D2/3 agonist radioligand
injection accelerates radioligand dissociation from D2/3 receptors in the tissue and proposed the use of pertussis
toxin to promote G‐protein decoupling from the receptors in vivo. Indeed, physiological effects of dopamine and
opioid receptor agonists were inhibited by pertussis toxin injections.212–214
This approach probes the nature of the high‐affinity state, that is, it seeks an answer to the question “is G‐
protein binding to the receptor significant for agonist binding to the receptor?” However, this question is not the
same as “do agonists bind to a subset of all receptors?,” which is addressed in other paradigms. As discussed in
Section 2, all receptors may be precoupled to G‐proteins. Moreover, G‐protein decoupling agents (pertussis toxin or
anything else) will have to be introduced locally into the region of interest rather than systemically through
intravenous, intraperitoneal, or subcutaneous injections. For brain imaging, that means that intrathecal and
intracerebral injections will have to be used. Such injections are technically challenging and hardly (if anyhow)
translatable to the clinic. Therefore, this paradigm has not yet been used for head‐to‐head comparisons of agonist
and antagonist radioligands.
5.3 | Current evidence on the existence of high‐affinity state in vivo
5.3.1 | Dopamine receptors
The majority of studies attempting to demonstrate the existence of high‐affinity state in vivo has concerned
dopamine D2/3 receptors. Agonists [
11C](−)NPA, [11C]MNPA, and [11C](+)PHNO were compared with antagonists
[11C]raclopride and [18F]fallypride. In some studies, these compounds were used in their unlabeled or 3H‐labeled
forms. A large portion of these studies failed to demonstrate the existence in vivo of the subpopulation of D2/3
receptors configured in the high‐affinity state (see Skinbjerg et al215 for review).
Binding site densities for D2/3 agonist and antagonist tracers were found to be equal in one study,
90 while in
another study the average relative abundance of D2/3‐high was found to be 79%,
193 which is close to the upper
extreme of such percentages determined in vitro.216 Saturation of [11C](+)PHNO binding in monkey brain was
found to be biphasic but the two binding sites most probably corresponded to D2 and D3 receptor subtypes rather
than to high‐ and low‐affinity states.217
In rats with brain lesions induced by the dopaminergic neurotoxin 6‐hydroxydopamine, binding levels of D2/3
antagonist [11C]raclopride and of D2/3 agonist [
3H]PHNO were increased to the same extent.194 No difference in
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baseline agonist binding relative to the healthy condition was found in dopamine β‐hydroxylase knockout (Dβh‐KO)
mice,103 in rats withdrawn from chronic ethanol and in amphetamine‐sensitized rats.194 In these three animal
models, an upregulation of D2/3‐high was previously demonstrated in vitro by the group of Seeman et al.
201,218–220
However, in vitro measurements of elevated striatal D2/3‐high in Dβh‐KO mice could not be replicated by the group
that performed the in vivo imaging study.103 Moreover, most of the data on the elevation of D2/3‐high in ethanol‐
withdrawn rats is based on comparison of Bmax values for antagonist radioligands in the presence and absence of
GppNHp,201,219 an indirect method of assessing D2/3‐high abundance, shortcomings of which are discussed in Van
Wieringen et al.216
In clinical studies of diseases where alteration of D2/3‐high was suspected, binding potentials of agonist tracers in
healthy and diseased subjects were similar,202,221–224 although some recent reports buck this trend.195,225
The dopamine D2/3 antagonist radioligand raclopride (
11C‐ or 3H‐labeled) was displaced by D2/3 agonist drugs in
a monophasic manner.86,196,197 In a more recent study, up to 70% of [11C]raclopride binding was displaced by D2/3
agonist quinpirole without any evidence of biphasicity.39
The majority of studies comparing agonist and antagonist tracers’ vulnerability to displacement by agonist
drugs found no difference in vulnerabilities,86,107,196 though some reports confirming greater vulnerability of
agonist tracers do exist 199,200 and the relative timing of tracer and drug administration were claimed to be
important.200
Nevertheless, D2/3 agonists did prove to be more sensitive than antagonists to endogenous dopamine levels in
anesthetized rodents,44 cats,90 primates,92,98,106 as well as in awake humans,93,102 though not in awake
rodents,86,194,196,203 with a single exception.199 However, lack of consistency in preclinical data on neurotrans-
mitter and agonist drug challenge raises a question whether this advantage of the agonists stems from their
preference for the high‐affinity state or from other factors (see Section 5.2.2).
For dopamine D1/5 receptors, an in vivo displacement curve was built in baboons using the D1‐antagonist [11C]
NNC‐112 and the D1‐agonist drug DAR‐0100A.198 Occupancies above 40% were not investigated, but the best‐fit
curve was monophasic, not supporting the existence of a high‐affinity receptor subpopulation.
5.3.2 | Serotonin receptors
A few head‐to‐head agonist‐antagonist comparisons done with serotonin receptor radioligands yielded ambiguous
results.
Two studies found that about 80‐90% of the specific binding of antagonist 5‐HT1A ligand [11C]WAY‐100635
could be displaced by the 5‐HT1A agonist 8‐OH‐DPAT,226,227 but in both cases only a single dose of the agonist was
tried, so it is impossible to say whether 8‐OH‐DPAT displaces [11C]WAY‐100635 in a monophasic or a biphasic
manner. In an ex vivo saturation study, the binding site density of 5‐HT1A agonist [3H]CUMI‐101 was 33% lower
than that of the antagonist [3H]MPPF in rat frontal cortex, but 82% higher in rat hippocampus.122 BPF values for
[11C]CUMI‐101 across the baboon brain were about 45% of BPF values for 5‐HT1A antagonist [11C]WAY‐100635,70
while in vitro Kd values for the two tracers were comparable, but these findings should be interpreted with caution
for reasons described in the subsection “Extracting density values from true binding potential measurements” of
Section 5.2.1. Yet another study found considerable differences between the binding patterns of 5‐HT1A agonist
[18F]F13174 and 5‐HT1A antagonist [18F]MPPF in marmosets: regional BPND values even did not correlate when
animals were imaged without the use of anesthesia.132 However, the variability of data (especially for [18F]F13174)
was high, so it is hard to draw any firm conclusions regarding the existence of separate 5‐HT1A receptor
subpopulations recognized by [18F]F13174 and [18F]MPPF from the study.
Regional BPND values of the 5‐HT2A agonist [11C]CIMBI‐36 were compared with regional BPND values of the
5‐HT2A antagonist [11C]MDL100907 in monkeys 137 and regional BPND values of another 5‐HT2A antagonist [18F]
altanserin in humans.139 Both analyses did yield deviations from linear correlation in the hippocampus and choroid
plexus, but these could all be explained by the binding of [11C]CIMBI‐36 to 5‐HT2C receptors. In a recent
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non‐human primate study, [11C]CIMBI‐36 turned out to be more sensitive than [11C]MDL100907 to fenfluramine‐
induced serotonin release,142 but, as discussed above for D2/3 radioligands, this does not per se prove that [
11C]
CIMBI‐36 preferentially binds to the high‐affinity state of 5‐HT2A receptors in vivo.
To sum up, the majority of data, both for dopamine and serotonin receptors, does not directly support the existence
of a receptor subpopulation in vivo to which agonists preferentially bind. There are some undisputable differences in the
behavior of agonist tracers and antagonist tracers, such as specific sensitivity of the former to anesthesia and greater
sensitivity to synaptic neurotransmitter levels, but the reason for these differences is not clear.
5.4 | Experimental data in light of the nature of the high‐affinity state
Some attempts to detect the high‐affinity state in vivo may have failed because the used radioligands were not
sufficiently subtype‐selective or lacked sufficient intrinsic acitivity via the canonical GPCR pathway.118,119,228 In
other cases, however, the reasons for failure were completely unclear. Therefore, the nature and functioning of the
high‐affinity state in vivo has remained elusive.
Two explanations of the failure to detect high‐ and low‐affinity states in vivo have been put forward. One
explanation proposes that all, or almost all, receptors are configured in the high‐affinity state in vivo 86 and
permanently precoupled to G‐proteins, so that these G‐proteins, at least their Gα subunits, do not dissociate from
the receptors after activation.215 Another explanation states that, whatever the baseline degree of receptor‐
G‐protein precoupling, receptors can and do recruit new G‐proteins when occupied by agonists, so high agonist
concentrations eventually make all receptors bind G‐proteins and thus convert to the high‐affinity state.196,198
Indeed, receptors have been subjected to high agonist (drug or neurotransmitter) concentrations in virtually all
experimental paradigms used for in vivo detection of the high‐affinity state (Table 2). In vivo imaging experiments
last for tens of minutes, while time constants for receptor and G‐protein activation and for receptor‐ligand and
receptor‐G‐protein binding vary from tens of milliseconds to a few seconds.37 Gradual G‐protein recruitment in
response to agonist binding can thus confound experimental outcomes in currently used paradigms and can
“inflate” the apparent relative abundance of the high‐affinity state in vivo. Indeed, in studies comparing the
vulnerability of dopamine D2/3 agonist and antagonist tracers to drug challenge, the lowest doses of D2/3 agonist
drugs and the dopamine release stimulator amphetamine (resulting in the lowest receptor occupancies and
therefore minimal G‐protein recruitment) tended to produce the greatest relative difference between agonist and
antagonist tracer displacement. In three such studies, the lowest dose of challenge drugs resulted in zero or
negative displacement of the antagonist [11C]/[3H]raclopride but positive (though small and not statistically
significant) displacement of agonist tracers [11C]/[3H]PHNO and [11C]/[3H]MNPA.86,107,196 Superior sensitivity of
D2/3 agonists to amphetamine‐induced dopamine release in humans compared to the D2/3 antagonist [11C]
raclopride was demonstrated at receptor occupancies of 22% or lower.93,102 Finally, the D2/3 agonist [
3H]PHNO
was found to be more vulnerable than [3H]raclopride to displacement by the agonist (−)NPA when this agonist was
co‐injected with the radioligands instead of being injected sometime before their administration, although this
study used non‐normalized “raw” specific binding as outcome measure.200
Comparison of the in vivo imaging results with available in vitro data on detection of the high‐affinity state
raises even more questions. There are no systematic reviews of in vitro studies assessing the percentage of
receptors configured in the high‐affinity state for nondopaminergic receptors. However, recently published reviews
dedicated to the affinity states of D2/3 receptors
216,229 demonstrate not only the lack of agreement but also the
absence of a trend in the assessments of the abundance of the high‐affinity state of D2/3 receptors in different
setups:
(i) Experiments in membrane homogenates from transfected cells and isolated tissues consistently showed that a
significant portion of D2/3 receptors is configured in the low‐affinity state. Only about 20% of dopamine D2/3
receptors in the rodent brain and about 30% in the human brain are in the high‐affinity state.216
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(ii) No high‐affinity state of D2/3 receptors could be detected on intact cells. In bovine pituitary membranes,
55% of D2/3 receptors were in the high‐affinity state, but intact dispersed pituitary cells had only
low‐affinity state.230 Similar results were demonstrated with transfected HEK293T and T‐REx‐293
cells expressing D2 receptors.
28,42 One study found 16% of D2 receptors on cultured rat pituitary adenoma
cells configured in the high‐affinity state using [3H]domperidone as a radioligand,231 but these results have
yet to be replicated.
(iii) Autoradiographic studies where densities (Bmax) of D2/3 receptors in tissue slices were estimated, tended to
produce lower Bmax values for agonist than for antagonist radioligands, but the variance between studies was
too high to consider the difference significant.229 The majority of antagonist vs agonist drug displacement
experiments demonstrated a single high‐affinity population of D2/3 receptors in tissue slices in vitro.229 This is
in agreement with the data from in vivo imaging (see Section 5.3.1).
To explain the low relative abundance of the high‐affinity state in membrane homogenates within the
precoupling model of receptor‐G‐protein interaction, one can assume that partial dissociation of receptor‐
G‐protein complexes occurs during membrane preparation, but the exact mechanism is hard to define.
Alternatively, one can assume the existence of a large intracellular reserve of receptors in the high‐affinity state.
In transfected cells, the affinity of agonist ligands used as PET tracers toward internalized D2/3 receptors was
shown to be about twofold lower than toward surface receptors,42 a change that would hardly be noticeable in
saturation or competition curves. However, the total densities of D2/3 receptors measured in membrane
homogenates by radioligand binding saturation and in vivo by PET are in good agreement,229 which does not
support the existence of extra D2/3 receptors that are detectable in vivo but are not found in membrane
homogenates.
The collision coupling model of receptor‐G‐protein interaction can be reconciled with measurements of the
high‐affinity state in membrane homogenates if one assumes that in these homogenates only a fraction of the
total G‐protein pool of the cell is available for recruitment to the receptors. Indeed, the number of G‐proteins in
living cells is likely equal to or much greater than the number of their cognate receptors.45,232,233 However,
given that G‐proteins are anchored to the lipid bilayer,234 it is not clear how such G‐protein reserve can both be
easily accessible in the living tissue and become lost in membrane homogenates. Especially the findings
of Seeman200 are puzzling in this regard. In that study, IC50 values for the displacement of [
3H](+)PHNO and
[3H]raclopride from striatal membranes by (−)NPA were measured. When radioligands and (−)NPA were added
to the membranes simultaneously, the IC50 value observed for [
3H](+)PHNO was sevenfold lower than for
[3H]raclopride. However, when (−)NPA was added to the membranes 30 minutes earlier than the radioligands,
the difference in IC50 values for [
3H](+)PHNO and [3H]raclopride was only twofold. Similar vulnerabilities of
[3H]raclopride and [3H](+)PHNO in the case of (−) NPA pre‐incubation could mean that (−)NPA can and does
stimulate G‐protein recruitment to all or almost all receptors in the membranes, while greater vulnerability of
[3H](+)PHNO in case of simultaneous addition may mean that in the absence of an agonist, only some receptors
are G‐protein‐bound and therefore accessible to [3H](+)PHNO. However, in those experiments, radioligands
were equilibrated with membrane homogenates for 2 hours before readout, which is much longer than the
pre‐incubation step. Therefore, even in the case of simultaneous addition of radioligands and (−)NPA, there
should have been enough time during the equilibration step for (−)NPA to elicit recruitment of “spare” G‐
proteins to the receptors.
The absence of the high‐affinity state of D2/3 receptors in isolated intact cells 28,42,230 is even harder to
reconcile with either of the two models mentioned above. Collision coupling at least provides a theoretical
explanation of the disappearance of high‐affinity state upon agonist addition due to a high level of GTP in living
cells. Still it remains puzzling why agonists force D2/3 receptors in dispersed cells from a natural tissue (bovine
pituitary) to uncouple from G‐proteins (convert into the low‐affinity state), but promote G‐protein recruitment
(conversion to the high‐affinity state) when they are acting on the same receptors in intact tissue.
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Switching from the G‐protein‐dependent high‐affinity state model to the oligomerization‐dependent model
leaves the same questions open: it is not clear how the degrees of receptor oligomerization can be different in
membranes, dispersed cells and living tissues. Moreover, observation of almost all receptors configured in high‐
affinity state in vivo is hard to reconcile with the oligomerization‐dependent model. At full oligomerization and full
agonist occupancy, cooperativity‐induced high‐affinity state can have a relative abundance of no more than 50%
(in the case of dimers), and higher values imply that few, if any, receptors are oligomerized.
6 | CONCLUSION
The concept of the high‐affinity state postulates that a certain subset of receptors in the living brain is primarily
responsible for signaling. Assessing the abundance of this subset is thus potentially very relevant for studies
concerning the responses of neurotransmission to pharmacological or physical stimuli and the dysregulation of
neurotransmission in neurological disorders.
A number of experimental paradigms have been developed for the estimation of the relative abundance of
receptors configured in the high‐affinity state. The high‐affinity state is preferentially recognized by agonists in
vitro, so the development of agonist PET tracers as tools for the noninvasive imaging of the high‐affinity state has
become popular in recent decades.
The greatest number of agonist tracers has been developed for dopamine D2/3 receptors, but agonist tracers for
dopamine D1, µ‐opioid, and muscarinic M2 receptors are also known, and in recent years, radiolabeled agonists for
serotonin 5‐HT1A and 5‐HT2A, κ‐opioid and muscarinic M1 receptors have appeared. It should be noted, however,
that for many of the nondopaminergic tracers the actual preference for the high‐affinity state has not been directly
tested, because functional agonism is often assumed to imply preferential binding to the high‐affinity state.
For dopamine, serotonin and κ‐opioid receptors, head‐to‐head comparisons of agonist and antagonist tracers
are now possible, while matching antagonist tracers for muscarinic M2 and µ‐opioid receptors have yet to be
developed. Given that, beyond head‐to‐head agonist‐antagonist comparisons, antagonist tracers are also suitable
for experiments like displacement curve generation (see Section 5.2.2), development of new antagonist tracers for
muscarinic M2 and µ‐opioid receptors with a pharmacological selectivity matching that of existing agonist tracers
will arguably be more useful for the assessment of the affinity states of these receptors than development of new
agonist tracers.
Agonist tracers appear to be more sensitive to endogenous neurotransmitter challenge, as was originally
expected. However, other expectations regarding agonist tracers have not been fulfilled. Agonist imaging did not
reveal alterations in the relative abundance of the high‐affinity state in neurological disorders. The benefits of
agonist tracers for the imaging of receptor occupancies by drugs have also not been proven.
Moreover, though the separation of GPCRs into subsets with high‐ and low‐affinity state is consistently
observed in membrane homogenates in vitro, data from preclinical and clinical experiments do not support the
existence of the high‐ and low‐affinity states in vivo. The majority of these data concerns dopamine D2/3 receptors
but recent results on serotonin receptors paint the same picture.
The relative abundance of the high‐affinity state in vivo may simply be close to (or equal to) 100%, making the
detection of low‐affinity state unfeasible. It is also possible that agonist drugs or tracers used for in vivo
experiments may inflate the relative abundance of the high‐affinity state.
Critical revision of experimental approaches and collection of experimental evidence for nondopaminergic
receptors will help clarify whether the high‐affinity state of GPCRs exists in vivo and whether agonist tracers really
have advantages over antagonist tracers because of their preferential binding to the high‐affinity state.
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APPENDIX
CALCULATION OF BINDING POTENTIALS
The ratio of the concentrations of specifically bound tracer (B) and free tracer (F) in the tissue at equilibrium is equal to
the ratio of available receptor density and ligand‐receptor affinity (Bmax/Kd) when the tracer only occupies a negligible
fraction of all receptors (Figure A1).
In practice, specifically bound tracer concentration B is often calculated as a difference between tracer
concentrations in a receptor‐rich region of interest and a receptor‐poor reference region. Free tracer
concentration, on the other hand, is replaced with directly measurable concentrations that are linearly dependent
on “true” F at equilibrium.192 These concentrations can be:
– Free tracer concentration in plasma (equal to F if the tracer is transferred from tissue to plasma by passive
diffusion);
– Total, that is, free and protein‐bound, tracer concentration in plasma;
– Nondisplaceable, that is, free and nonspecifically bound, tracer concentration in tissue.
To determine tracer concentration in plasma (whether free or total) one needs to obtain arterial plasma
samples, which is an invasive procedure. Therefore, the last option is the most popular: tracer concentration in
receptor‐rich tissue is related to tracer concentration in receptor‐poor tissue.
Binding potentials are defined at equilibrium. Plasma and tissue concentrations of a tracer can be directly equilibrated
with each other by administering the tracer in an infusion but such paradigms are hard to implement. Therefore, in most
positron emission tomography (PET) and single‐photon emission computed tomography (SPECT) studies tracer is
administered via a simple bolus injection. In that case, to calculate binding potentials, time‐activity curves for regions of
interest are used as input data for so‐called kinetic modeling. A compartmental model is built up based on relevant
theories. Tracer distribution is described in terms of its transfer between virtual compartments (like “free tracer,”
“nonspecifically bound tracer,” and “specifically bound tracer”). The model is fitted to the time‐activity curves acquired by
the PET camera. If the model can adequately describe the experimental curves, the values of individual kinetic parameters
or their combinations are determined from the model fit. Fewer fitting parameters often mean a more robust fit, so many
simplifying assumptions are often made. Graphical analyses, simplifying the fitting process to linear regression, are also
widely used.235,236 Fitted parameters are then used to obtain binding potentials, essentially by extrapolating the kinetics
observed in the imaging experiments to the situation of equilibrium.
F IGURE A1 Relationship between the fraction of ligand‐occupied receptors and B/F ratio. At equilibrium,
B/Bmax = F/(F + Kd), therefore B/F = Bmax/(F + Kd). If F ≪ Kd, then B ≪ Bmax and B/F ~ Bmax/Kd. Note that at low
concentrations (F/Kd ≪ 1), the ligand occupies only a small part of total receptor population, and the B/F ratio
(binding potential) is stable (left part of the graph)
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